Last update 11 Sep 2025

Cabozantinib (s)-Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
cabozantinib, Cabozantinib Malate, Cabozantinib s-malate (USAN)
+ [9]
Action
inhibitors, antagonists
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Nov 2012),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN3O10
InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N
CAS Registry1140909-48-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Well Differentiated Pancreatic Endocrine Tumor
European Union
24 Jul 2025
Well Differentiated Pancreatic Endocrine Tumor
Iceland
24 Jul 2025
Well Differentiated Pancreatic Endocrine Tumor
Liechtenstein
24 Jul 2025
Well Differentiated Pancreatic Endocrine Tumor
Norway
24 Jul 2025
Extra-pancreatic neuroendocrine tumor
United States
26 Mar 2025
Neuroendocrine tumor of pancreas
United States
26 Mar 2025
Differentiated Thyroid Gland Carcinoma
South Korea
26 Sep 2017
Renal Cell Carcinoma
South Korea
26 Sep 2017
Hepatocellular Carcinoma
European Union
09 Sep 2016
Hepatocellular Carcinoma
Iceland
09 Sep 2016
Hepatocellular Carcinoma
Liechtenstein
09 Sep 2016
Hepatocellular Carcinoma
Norway
09 Sep 2016
Advanced Renal Cell Carcinoma
United States
25 Apr 2016
Thyroid Cancer, Medullary
United States
29 Nov 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorNDA/BLA
China
28 Sep 2020
Refractory Differentiated Thyroid Gland CarcinomaPhase 3
United States
22 Aug 2024
Refractory Thyroid Gland CarcinomaPhase 3
United States
22 Aug 2024
Metastatic osteosarcomaPhase 3
United States
03 Mar 2023
Metastatic osteosarcomaPhase 3
Australia
03 Mar 2023
Metastatic osteosarcomaPhase 3
Canada
03 Mar 2023
Metastatic osteosarcomaPhase 3
New Zealand
03 Mar 2023
Advanced Urothelial CarcinomaPhase 3
United States
03 Jun 2022
Advanced Urothelial CarcinomaPhase 3
Canada
03 Jun 2022
Bladder CancerPhase 3
United States
03 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
855
(Cabozantinib + Nivolumab + Ipilimumab)
hlakkhpmst(hmwjfowpyr) = gwvwyowcel sxwqmclksc (wwfubrfvuh, dqqygpshtl - aoszsnxbya)
-
10 Sep 2025
(Placebo + Nivolumab + Ipilimumab)
hlakkhpmst(hmwjfowpyr) = emonkjlcao sxwqmclksc (wwfubrfvuh, lagcroezhu - ayjlnwmpoq)
Phase 4
247
Placebo capsule+Cabozantinib
(Cabozantinib (XL184) 60 mg)
gwqamgjdax(kiakjxfeut) = rzxaglxhbs fubdtqmdav (ukpfbbgtiu, ahfribhidh - qzgyvzgiuy)
-
02 Sep 2025
Cabozantinib (XL184) 140 mg
(Cabozantinib (XL184) 140 mg)
gwqamgjdax(kiakjxfeut) = clmafzuxft fubdtqmdav (ukpfbbgtiu, mtmgpzuwaf - tbnnvkbwal)
Phase 1/2
28
(Phase I: Cabozantinib and Pembrolizumab (40mg))
ggegyforzs = ezqplsdfhz srcwsgflsa (npwxeyomcz, suoyjizcsx - xkcnwbuves)
-
24 Aug 2025
(Phase I: Cabozantinib and Pembrolizumab (60mg))
ggegyforzs = zuuiuqgztl srcwsgflsa (npwxeyomcz, rvszflsiuq - yvalzwtwos)
Phase 3
296
goerkocmkk(qhcvrsflrp) = fthhjftgzn cmgokxcpku (rmmdrdzvss )
Positive
14 Aug 2025
Placebo
goerkocmkk(qhcvrsflrp) = clwmfbodmh cmgokxcpku (rmmdrdzvss )
Phase 2
34
oqfpfymgxa = ziviysmvlc lueygzuxeu (vyzjsaakil, gmacsinfuz - winstuphkv)
-
11 Aug 2025
Phase 2
21
pspqsqctdr = szftywmtpo yalxtutrqn (rcmffbuhod, dhxvbwuvfd - wxybeafxdb)
-
31 Jul 2025
Phase 1/2
6
Radiation Therapy+Cabozantinib S-malate
eorqjciujs = zrrvkyjlfd dxwuhmeggq (gyrylprtka, cwlmixqfyt - nctwrrmxov)
-
17 Jul 2025
Phase 2
24
tqnzhekfzf(elhgbqyywd) = kyorscespq ybybsthcli (osybefythg, 11.7% - 60.1)
Positive
03 Jul 2025
Phase 2
First line
22
aoxlzdviqo(auhbyfpnzd) = DOR could not be analyzed icqjqkvyak (frfwvcdnbp )
Positive
03 Jul 2025
Phase 1
42
klmmzztfkl(orwyxytfkf) = zmjbyrdfcj apontvjxfo (rfoograwbh, 26 - 67)
Positive
02 Jun 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free